Press Release: Amarex Clinical Research : Amarex Achieves Orphan Drug Designation for Gibson Oncology's Novel LMP744 Cancer Treatment
New Designation Marks Milestone in Glioblastoma Treatment Decades in the Making with Glioma Treatment that Crosses Blood Brain Barrier at Ten Times Concentration Needed to Kill Cancer Cells...
Read full article »
Amarex is a contract research firm that provides clinical regulatory strategy and product development services for drug and medical device approvals.
Read more